UroGen Pharma is trading 5.09% lower at $34.74, with no clear company-specific catalyst identified. - On October 16, 2026, the available news search surfaced no clear company announcement; recent coverage described company-specific news as light. - The Nasdaq was down 1.32% and the S&P 500 down 0.60%; healthcare rose 2.12%. Broad-market weakness may be contributing, but the specific cause remains uncertain.